Presentation on theme: "Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine."— Presentation transcript:
Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine INtervention) 1- The ORIGIN Trial Investigators. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309-318.
15 392 Patients screened for eligibility 13 765 Patients included in run-in 12 611 Patients randomized 6319 Received n-3 fatty acids 6292 Received placebo 1627 Excluded: 322 Did not meet inclusion criteria 10 Declined to participate 1295 Had other reasons 1154 Excluded: 356 Had ineligible plasma glucose 42 Were ineligible for other reasons 397 Were nonadherent in run-in 264 Withdrew consent 95 Had other reasons 6220 Had known outcome status 61 Did not have final outcome status 14 Withdrew consent 38 Did not give consent to extension 9 Were lost to follow-up 6208 Had known outcome status 47 Did not have final outcome status 18 Withdrew consent 20 Did not give consent to extension 9 Were lost to follow-up 6281 Were included in the analysis 6255 Were included in the analysis 38 Excluded by health authorities 37 Excluded by health authorities Median follow-up: 6.2 years
% Influence of the n-3 fatty acid regimen on mortality
% Influence of the n-3 fatty acid regimen on cardiovascular events
Conclusions Daily 1-g dose of n-3 fatty acids did not prevent death or any cardiovascular outcome in hyperglycemic or diabetic patients with high cardiovascular risk compared with placebo
Your consent to our cookies if you continue to use this website.